M&A Archives - Page 56 of 448

1 minute read

M&A
News

Expro Agrees To Acquire Aberdeen Scotland-Based Coretrax For $210M, Expanding Well Construction & Intervention Solutions

February 13, 2:51 AM

Total consideration to be paid at closing is approximately $210 million, including at least $75 million of cash and up to 6.75 million newly issued Expro common shares. The cash component of the proposed

XPRO

2 minute read

Why Ecommerce Platform ContextLogic Shares Are Rocketing Today?

By Lekha Gupta

February 12, 11:18 AM

ContextLogic Inc (NASDAQ: WISH) soars 35% as it plans to divest its Wish ecommerce platform assets to Qoo10 for $173 million, representing a significant premium. Post-divestment, WISH will be debt-free with substantial net cash proceeds and aims to monetize its tax assets, exploring financial sponsor opportunities for value realization.

WISH

2 minute read

Health Care Company Gilead Sciences Announces Acquisition of CymaBay Therapeutics

By Benzinga Insights

February 12, 11:10 AM

Gilead Sciences (NASDAQ:GILD) has announced an acquisition of CymaBay Therapeutics (NASDAQ:CBAY) that is expected to be completed in…

CBAY

2 minute read

Assure Holdings Corp. Announces Business Combination With Danam Health, Inc.; Assure Will Change Its Name To “Danam Health Holdings Corp.”

By Benzinga Newsdesk

February 12, 10:59 AM

Assure Holdings Corp. ("Assure") (NASDAQ:IONM) today announced that it has entered into a definitive Agreement and Plan of Merger (the "Merger Agreement") with Danam Health, Inc. ("Danam") under which Danam will merge

IONM

1 minute read

Martin Marietta Makes Splash In Southeast, $2.05B Acquisition Boosts Aggregates Business

By Lekha Gupta

February 12, 10:46 AM

Martin Marietta Materials announces a strategic acquisition of 20 active operations from BWI Southeast for $2.05 billion in cash, expanding its presence in key southeastern markets such as Nashville and Miami.

CRH

2 minute read

Drugmaker Gilead Sciences Scoops Up Liver-Disease Focused CymaBay Therapeutics For $4.3B

By Vandana Singh

February 12, 10:22 AM

Gilead Sciences will acquire CymaBay Therapeutics for $4.3 billion, advancing liver disease treatment with seladelpar. FDA priority review was granted, and there is potential for significant revenue growth.

CBAY

3 minute read

Gilead Sciences Expands Liver Portfolio With Acquisition Of CymaBay Therapeutics For $32.50/Share Or A Total Equity Value Of $4.3B

By Benzinga Newsdesk

February 12, 9:31 AM

-- Gilead Adds Seladelpar to Portfolio, a PPARδ Agonist for the Treatment of Primary Biliary Cholangitis (PBC) with FDA Priority Review and Anticipated U.S. Approval in Third Quarter of 2024 ---- Seladelpar Phase 3 Data

CBAY

2 minute read

Sony Clinches Historic $600M Deal for Michael Jackson’s Music Catalog

By Anusuya Lahiri

February 12, 9:16 AM

Sony Group Corp (NYSE: SONY) to acquire 50% of Michael Jackson's music catalog for $600 million, solidifying his legacy and Sony's financial growth.

SONY

1 minute read

Daxor Announces Two Significant New Customer Transactions With The Co’s BVA-100 In January; No Financial Terms Disclosed

By Benzinga Newsdesk

February 12, 9:15 AM

Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology today announces two significant new customer transactions with Daxor's BVA-100™ (Blood Volume Analyzer) in January, marking

DXR

2 minute read

SP Plus Stockholders Approve Merger With Metropolis Technologies

By Benzinga Newsdesk

February 12, 9:13 AM

SP Plus Corporation ("SP+") (NASDAQ:SP) today announced that at its special meeting of stockholders held on February 9, 2024 (the "Special Meeting"), SP+ stockholders voted to approve the previously announced Agreement